Department of Medicine & Therapeutics, Prince of Wales Hospital
Shatin, Hong Kong
NCT Number: NCT02593201
Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent peritonitis remains the major cause of peritoneal failure. A recent study showed that an elevated bacterial DNA fragment levels in PD effluent 5 days prior to the completion of antibiotics predicts the development of relapsing or recurrent peritonitis episodes. We hypothesize that prolonged antibiotic therapy in PD patients with peritonitis and high PD effluent bacterial DNA fragment levels could prevent the development of relapsing and recurrent peritonitis. We plan to conduct a randomized control study of 360 patients with PD peritonitis. After inform consent, they will be randomized to receive one additional week of the effective antibiotic treatment (the Preemptive Treatment Group) or no additional treatment (the Control Group). Specimens of PD effluent will be collected 5 days prior to the completion of antibiotics for the measurement of bacterial DNA fragments. All patients will be followed for 6 months after completion of antibiotic therapy for the development of relapsing, recurrent, or repeat peritonitis episodes. Our study will determine the efficacy of a test-before-treat algorithm that could reduce the incidence of relapsing and recurrent peritonitis and, at the same time, minimize the unnecessary use of prolonged antibiotic treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Shatin, Hong Kong
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To continue with the existing effective antibiotic therapy for one extra week
Usual duration of effective antibiotic therapy therapy
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
by record review
Time frame: 6 months
by record review
Time frame: 6 months
Time frame: 6 months
Chinese University of Hong Kong
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07634211
Behavior, Motor Activity
Muğla, Turkey (Türkiye)
View Trial DetailsNCT05449067
Chronic Disease, Disease Attributes
Guangzhou, Guangdong, China
View Trial DetailsNCT04006093
Chronic Disease, Chronic Renal Insufficiency
Caen, France
View Trial DetailsNCT06330194
Autoimmune Diseases, Chronic Disease
Copenhagen, Denmark
View Trial Details